IFO50479 NAGL-1
Cell information
Cell type：general cells (View Pricing Information)
| JCRB No. | IFO50479 | Cell Name | NAGL-1 |
|---|---|---|---|
| Profile | The CDR III of this line has been sequenced. | Other Name | |
| Animal | human | Strain | |
| Genus | Homo | Species | sapiens |
| Sex | F | Age | |
| Identity | available | Tissue for Primary Cancer | hemo-lymphocytic |
| Case history | leukemia | Metastasis | |
| Tissue Metastasized | Genetics | ||
| Life Span | infinite | Crisis PDL | |
| Morphology | round | Character | leukemia, B cells |
| Classify | tumor | Established by | Abe, A. and Emi, N. |
| Registered by | Emi,N. | Regulation for Distribution | |
| Comment | Year | 1998 | |
| Medium | Iscove's modification of Dulbecco's medium with 20% heat-inactivated fetal bovine serum | Methods for Passages | dilution |
| Cell Number on Passage | 1-2 x 10^6 cells/ml | Race | |
| CO2 Conc. | 5 % | Tissue Sampling | B cells |
| Tissue Type |
| Detection of virus genome fragment by Real-time PCR | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Detected DNA Virus | tested | Detected RNA Virus | tested | ||||||
| CMV | - | parvoB19 | - | HCV | - | HTLV-1 | - | ||
| EBV | - | HBV | - | HIV-1 | - | HTLV-2 | - | ||
| HHV6 | - | HTLV-1 | - | HIV-2 | - | HAV | - | ||
| HHV7 | - | HTLV-2 | - |
-/negative. +/positive. nt/not tested. (positive (+) does not immediately mean the production of infectious viral particles.) |
|||||
| BKV | - | HIV-1 | - | ||||||
| JCV | - | HIV-2 | - | ||||||
| ADV | - | HPV18 | - | ||||||
| Notes | |||||||||
| Reference | |
|---|---|
| Pubmed id:10071461 | Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1. Kasai M,Akatsuka Y,Emi N,Taji H,Kohno A,Abe A,Tanimoto M,Kodera Y,Saito H Int J Hematol. 1999 Feb;69(2):112-8 |
| Images |
|---|
  |
LOT Information
Viability/Growth rate/Cell number are represented as actual values measured at lot presentation in JCRB, but are not guaranteed values. Additionally, the doubling time is a rough value measured during passages.| Cell No. | IFO50479 | Cell Name | NAGL-1 |
|---|---|---|---|
| LOT No. | 1142 | Lot Specification | distribution |
| Medium | Iscov's modification of D.MEM, 80% ; heat-inactivated FBS, 20% | Temperature | 37 C |
| Cell Density at Seeding | 1.8 x 10^6 cells/ml | Methods for Passages | Dilution. Split ratio, 1/2 - 1/3. For collection of cells, centrifuge at 1,200 rpm for 5 min. |
| Doubling Time | Cell Number in Vial (cells/1ml) | 7.2 x 10^6 | |
| Viability at cell freezing (%) | 90 | Antibiotics Used | free |
| Passage Number | Unknown (12 at IFO) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | NP, G6PD (type B), MD, AST |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | No | Exoteric Gene | |
| Medium for Freezing | 10% DMSO, 20% serum (final conc.)-culture medium | CO2 Conc. | 5 % |
| Viability immediately after thawing (%) | Additional information |
| Cell No. | IFO50479 | Cell Name | NAGL-1 |
|---|---|---|---|
| LOT No. | 11292013 | Lot Specification | distribution |
| Medium | Iscove's modification of Dulbecco's medium with 20% heat-inactivated fetal bovine serum (GIBCO Cat. # 10091). | Temperature | 37C |
| Cell Density at Seeding | 1.0 - 1.6 x 10^6 cells/mL | Methods for Passages | dilution |
| Doubling Time | Cell Number in Vial (cells/1ml) | 1.3 x 10^7 (cells/1 | |
| Viability at cell freezing (%) | Antibiotics Used | free | |
| Passage Number | Unknown (19 at bank) | PDL | |
| Sterility: MYCOPLASMA | - | Sterility: BACTERIA | - |
| Sterility: FUNGI | - | Isozyme Analysis | G6PD(typeB),NP,LDH were examined. Human,not HeLa |
| Chromosome Mode | Chromosome Information | ||
| Surface Antigen | DNA Profile (STR) | ||
| Adhesion | Exoteric Gene | ||
| Medium for Freezing | CO2 Conc. | 5% | |
| Viability immediately after thawing (%) | 90.7 | Additional information |